Evidence map›Paper›PMID 35011044›Full record

ReviewNutrients2021

Gut Microbiota and Complications of Type-2 Diabetes.

Camelia Oana Iatcu, Aimee Steen, Mihai Covasa

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 224 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
224citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

224 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Review
  8. Review
  9. The Microbiota as a Potential Cause of Disease.Diseases (Basel, Switzerland) · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

164 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Camelia Oana IatcuCollege of Medicine and Biological Sciences, Stefan cel Mare University of Suceava, 720229 Suceava, Romania.
Aimee SteenDepartment of Basic Medical Sciences, College of Osteopathic Medicine, Western University of Health Sciences, Pomona, CA 91766, USA.ORCID 0000-0002-9245-5349
Mihai CovasaCollege of Medicine and Biological Sciences, Stefan cel Mare University of Suceava, 720229 Suceava, Romania.ORCID 0000-0002-6266-4457

Funding

European Regional Development Fund through Competitiveness Operational Program 120/16.09.2016.
6 · The paper itself

Abstract

The gut microbiota has been linked to the emergence of obesity, metabolic syndrome and the onset of type 2 diabetes through decreased glucose tolerance and insulin resistance. Uncontrolled diabetes can lead to serious health consequences such as impaired kidney function, blindness, stroke, myocardial infarction and lower limb amputation. Despite a variety of treatments currently available, cases of diabetes and resulting complications are on the rise. One promising new approach to diabetes focuses on modulating the gut microbiota with probiotics, prebiotics, synbiotics and fecal microbial transplantation. Differences in gut microbiota composition have been observed in preclinical animal models as well as patients with type 2 diabetes and complications such as diabetic nephropathy, diabetic retinopathy, diabetic neuropathy, cerebrovascular disease, coronary heart disease and peripheral artery disease compared to healthy controls. Severity of gut microbiota dysbiosis was associated with disease severity and restoration with probiotic administration in animal models and human patients has been associated with improvement of symptoms and disease progression. Characterizing the gut microbiota dysbiosis in different diseases and determining a causal relationship between the gut microbiota and disease can be beneficial in formulating therapeutic interventions for type 2 diabetes and associated complications. In this review, we present the most important findings regarding the role of the gut microbiota in type 2 diabetes and chronic complications as well as their underlying mechanisms.

Indexed as

Amino AcidsAnimalsChromiumDiabetes Mellitus, Type 2Diabetic NephropathiesDiabetic RetinopathyDysbiosisFecal Microbiota TransplantationGastrointestinal MicrobiomeHumansInsulin ResistanceNicotinic AcidsPatient AcuityPrebioticsProbioticsSynbioticsAmino AcidsChromiumglucose tolerance factorNicotinic AcidsPrebioticsdiabetes complicationsgut microbiota dysbiosismacrovascular complicationsmicrovascular complicationsnephropathiesretinopathies

Identifiers

PMID35011044
PMCPMC8747253

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.